日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Obesity in Type 1 Diabetes: Moving Beyond the "Lean" Disease Paradigm to Understand Risk, Complications, and Treatment

型糖尿病合并肥胖:超越“瘦型”疾病范式,了解风险、并发症和治疗

Tentolouris, Anastasios; Koufakis, Theocharis; Fousteris, Evangelos

Nutritional Interventions in Type 1 Diabetes: Boosting Residual GLP-1 Responses-Is It an Option?

型糖尿病的营养干预:增强残余 GLP-1 反应——这是一种选择吗?

Grammatiki, Maria; Tsekmekidou, Xanthippi; Koufakis, Theocharis; Kotsa, Kalliopi

One-Hour Post-Load Glucose Is Associated with Multisystem Complications in People Living with Obesity

餐后一小时血糖与肥胖人群的多系统并发症相关

Mixaki, Ioanna; Prokopakis, Michalis G; Dimakopoulos, Georgios; Filippatos, Theodosios D; Kotsa, Kalliopi; Koufakis, Theocharis

Risk Communication and Infodemic Misframing in Legionella spp. Environmental Surveillance: An Infodemiology Case Study

军团菌属环境监测中的风险沟通和信息疫情误判:信息流行病学案例研究

Papadakis, Antonios; Koufakis, Eleftherios; Raptakis, Nikolaos; Pitsoulis, George; Kamekis, Apostolos; Chochlakis, Dimosthenis; Psaroulaki, Anna; Lagiou, Areti

Factors Associated with GLP-1 Receptor Agonist Use in Patients with Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Retrospective Propensity-Score Matched Analysis

2型糖尿病合并动脉粥样硬化性心血管疾病患者使用GLP-1受体激动剂的相关因素:一项回顾性倾向评分匹配分析

Vournas, Georgios; Mourgos, Leonidas; Doumas, Michael; Liberopoulos, Evangelos N; Kotsa, Kalliopi; Koufakis, Theocharis

GLP-1 Receptor Agonists in Acute Ischemic Stroke and Secondary Stroke Prevention: A Narrative Review of Preclinical and Clinical Evidence

GLP-1受体激动剂在急性缺血性卒中和卒中二级预防中的应用:临床前和临床证据的叙述性综述

Samanidou, Valentini; Tsamis, Konstantinos; Ceasovschih, Alexandr; Koufakis, Theocharis; Patoulias, Dimitrios; Rizos, Evangelos C; Rizzo, Manfreddi; Milionis, Haralampos; Barkas, Fotios

New Opportunities Beyond Intensive Insulin Therapy for Improving Vascular Health of People Living With Type 1 Diabetes

除了强化胰岛素治疗外,改善1型糖尿病患者血管健康的新机遇

Popovic, Djordje S; Kender, Zoltan; Koufakis, Theocharis

CONFIDENCE in the safety and efficacy of dual therapy with an SGLT-2 inhibitor and finerenone in patients with chronic kidney disease and type 2 diabetes

对SGLT-2抑制剂联合非奈利酮治疗慢性肾病合并2型糖尿病患者的安全性和有效性充满信心

Georgianos, Panagiotis I; Koufakis, Theocharis; Arampatzis, Spyridon; Liakopoulos, Vassilios

Pediatric Familial Hypercholesterolemia: Targeting Intestinal Absorption and Other Therapeutic Strategies

儿童家族性高胆固醇血症:靶向肠道吸收及其他治疗策略

Arvanitakis, Konstantinos; Chatzikalil, Elena; Antza, Christina; Topalidis, Christos; Kalopitas, Georgios; Solomou, Elena; Kotsis, Vasilios; Germanidis, Georgios; Koufakis, Theocharis; Doumas, Michael

Strong Association Between MiRNA Gene Variants and Type 2 Diabetes Mellitus in a Caucasian Population

在白种人群中,miRNA基因变异与2型糖尿病之间存在显著关联

Manthou, Eleni; Tsekmekidou, Xanthippi; Tsetsos, Fotis; Koufakis, Theocharis; Grammatiki, Maria; Rakintzi, Pantelitsa; Melidou, Eirini; Karaliolios, Georgios; Paschou, Peristera; Papanas, Nikolaos; Kotsa, Kalliopi